Details

Autor(en) / Beteiligte

• Tabariès, Sébastien
• Annis, Matthew G.
• Lazaris, Anthoula
• Petrillo, Stephanie K.
• Huxham, Jennifer
• Abdellatif, Amri
• Palmieri, Vincent
• Chabot, Jaclyn
• Johnson, Radia M.
• Van Laere, Steven
• Verhoef, Cornelis
• Hachem, Yasmina
• Yumeen, Sara
• Meti, Nicholas
• Omeroglu, Atilla
• Altinel, Gulbeyaz
• Gao, Zu-Hua
• Yu, Alan S. L.
• Grünhagen, Dirk J.
• Vermeulen, Peter
• Metrakos, Peter
• Siegel, Peter M.

Titel

Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the replacement type growth pattern

Ist Teil von

• Communications biology, 2021-06, Vol.4 (1), p.657-657, Article 657

Ort / Verlag

London: Nature Publishing Group

Erscheinungsjahr

2021

Link zum Volltext

Quelle

EZB Free E-Journals

Beschreibungen/Notizen

• Abstract Claudin-2 promotes breast cancer liver metastasis by enabling seeding and early cancer cell survival. We now demonstrate that Claudin-2 is functionally required for colorectal cancer liver metastasis and that Claudin-2 expression in primary colorectal cancers is associated with poor overall and liver metastasis-free survival. We have examined the role of Claudin-2, and other claudin family members, as potential prognostic biomarkers of the desmoplastic and replacement histopathological growth pattern associated with colorectal cancer liver metastases. Immunohistochemical analysis revealed higher Claudin-2 levels in replacement type metastases when compared to those with desmoplastic features. In contrast, Claudin-8 was highly expressed in desmoplastic colorectal cancer liver metastases. Similar observations were made following immunohistochemical staining of patient-derived xenografts (PDXs) that we have established, which faithfully retain the histopathology of desmoplastic or replacement type colorectal cancer liver metastases. We provide evidence that Claudin-2 status in patient-derived extracellular vesicles may serve as a relevant prognostic biomarker to predict whether colorectal cancer patients have developed replacement type liver metastases. Such a biomarker will be a valuable tool in designing optimal treatment strategies to better manage patients with colorectal cancer liver metastases.